Ribbon Bio launched an early‑access program for its cell‑free manufacturing of long synthetic DNA, offering linear molecules up to ~11 kb with reported accuracy above 90% and average ~95% for linear products. The in vitro process eliminates bacterial proteins and endotoxins, which Ribbon positions as crucial for cell‑and‑gene therapy and vaccine customers navigating GMP and regulatory expectations. Ribbon emphasized its MiroSynth platform evolution and pricing that scales by length and complexity. The product targets developers requiring longer constructs for mRNA vaccines, personalized cancer vaccines, and gene therapies and reflects growing commercial demand for high‑integrity, non‑bacterial DNA manufacturing.